long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
Published 6 months ago • 100 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
1:40
long-term follow-up of luspatercept: response duration and progression to aml
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
3:40
no sound reblozyl® (luspatercept-aamt) for anaemia
-
4:16
how are high risk and low risk mds defined? #mds
-
![surprises in coagulation testing–prolonged aptt & pt case [hot topic]](https://i.ytimg.com/vi/XNCwpA-1ZCg/mqdefault.jpg)
18:39
surprises in coagulation testing–prolonged aptt & pt case [hot topic]
-
1:31
overall survival of patients following treatment with luspatercept in the medalist trial
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
1:26
durable symptom improvement in ntd thalassemia treated with luspatercept in the beyond trial
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
3:54
results of medalist: luspatercept reduces transfusion burden in mds
-
1:06
long-term outcomes of the ocean study: melflufen is superior to pomalidomide in r/r myeloma